Opinion

Video

Defining and Managing Steroid Refractory Chronic GvHD

Author(s):

Preet M. Chaudhary, MD, PhD,Noah Merin, MD, PhD

Dr. Merin defines steroid refractory chronic GvHD, explains how to determine when patients become steroid-refractory and discusses treatment approach for this population.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Related Content